Aclaris Therapeutics, Inc. 8-K

What Happened

• Aclaris Therapeutics, Inc. announced the results of its 2026 annual meeting of stockholders held on June 4, 2026. Of 139,663,680 shares outstanding as of the record date, 112,499,671 shares (about 80.55%) were present or represented by proxy.
• Stockholders elected two directors — Anand Mehra, M.D., and Maxine Gowen, Ph.D. — to serve until the 2029 annual meeting. They received 83,063,569 (Mehra) and 84,209,108 (Gowen) votes in favor, with broker non‑votes of 19,360,478 on those elections.
• On an advisory basis, the company’s named executive officer compensation ("say‑on‑pay") was approved: 83,370,124 votes for, 9,734,691 against, and 34,378 abstentions (19,360,478 broker non‑votes).
• The Audit Committee’s selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal 2026 was ratified: 112,322,811 for, 159,714 against, and 17,146 abstentions.

Key Details

• Record date shares outstanding: 139,663,680.
• Shares present/represented at meeting: 112,499,671 (≈80.55%).
• Director votes: Anand Mehra — 83,063,569 for, 10,075,624 withheld; Maxine Gowen — 84,209,108 for, 8,930,085 withheld. Broker non‑votes: 19,360,478.
• Say‑on‑pay: 83,370,124 for; 9,734,691 against; 34,378 abstained. Auditor ratification: 112,322,811 for; 159,714 against; 17,146 abstained.

Why It Matters

• These governance votes finalize leadership and auditor relationships that affect oversight of company strategy and financial reporting. Director elections secure board continuity through 2029; auditor ratification confirms continuity in external audit oversight for 2026.
• The strong but not unanimous say‑on‑pay vote (with roughly 9.7 million opposing votes) is advisory but signals investor sentiment on executive compensation and is a measure management and the board monitor when setting pay practices.
• The presence of significant broker non‑votes on contested matters indicates a portion of shares (often held by brokerage firms without instructions) did not count toward certain elections, which can affect vote totals on non‑routine proposals.